General Motors is laying off about 1,000 workers worldwide, shedding costs as it tries to compete in a crowded global ...

The following is a summary of “Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized ...

There have been a slew of studies recently supporting the notion that the same mechanisms that help folks lose weight ...

A new study provides more evidence that GLP-1 RAs don’t raise the risk for pancreatic cancer and may in fact offer some protection.

They’re used to treat type 2 diabetes and obesity.These drugs curb the cravings for high-calorie foods, helping users eat ...

Over the past three decades, there has been a startling increase in the prevalence of obesity across the U.S., at least ...

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...

For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with reduced mortality, myocardial ...

Thank you for standing by. My name is John, and I’ll be your conference operator today. At this time I would like to welcome everyone to the Allurion Third Quarter Earnings Call. All lines have been ...

Structure Therapeutics, Inc. Sponsored ADR ( (GPCR) ) has released its Q3 earnings. Here is a breakdown of the information Structure ...

“We are in a period of great momentum and execution at Structure Therapeutics ... profile of GSBR-1290 as a potential best-in-class oral small molecule GLP-1 receptor (GLP1-R) agonist. We also plan to ...

Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or ...